Menu
Search
|

Menu

Close
X

PTC Therapeutics Inc PTCT.OQ (NASDAQ Stock Exchange Global Select Market)

42.83 USD
-0.16 (-0.37%)
As of Jul 17
Previous Close 42.99
Open 43.09
Volume 75,052
3m Avg Volume 250,689
Today’s High 43.47
Today’s Low 42.55
52 Week High 48.81
52 Week Low 27.55
Shares Outstanding (mil) 41.39
Market Capitalization (mil) 812.47
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
54
FY18
265
FY17
194
FY16
83
EPS (USD)
FY19
-1.291
FY18
-2.688
FY17
-2.074
FY16
-4.176
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
6.62
7.92
Price to Book (MRQ)
vs sector
4.78
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
83.22
14.56
LT Debt to Equity (MRQ)
vs sector
83.22
10.21
Return on Investment (TTM)
vs sector
-37.56
14.49
Return on Equity (TTM)
vs sector
-64.70
15.79

EXECUTIVE LEADERSHIP

Michael Schmertzler
Independent Chairman of the Board, Since 2004
Salary: --
Bonus: --
Stuart Peltz
Chief Executive Officer, Director, Since 1998
Salary: $658,819.00
Bonus: $922,347.00
Emily Hill
Principal Financial Officer, Treasurer, Since 2019
Salary: --
Bonus: --
Marcio Souza
Chief Operating Officer, Since 2017
Salary: $450,225.00
Bonus: $360,180.00
Mark Boulding
Executive Vice President, Chief Legal Officer, Since 2017
Salary: $434,120.00
Bonus: $312,567.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Corporate Ct
SOUTH PLAINFIELD   NJ   07080-2400

Phone: +1908.2227000

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

SPONSORED STORIES